Yalonda Howze - 02 Feb 2026 Form 4 Insider Report for Generation Bio Co. (GBIO)

Signature
/s/ Shawna-Gay White, Attorney-in-Fact
Issuer symbol
GBIO
Transactions as of
02 Feb 2026
Net transactions value
-$2,792
Form type
4
Filing time
04 Feb 2026, 16:05:25 UTC
Previous filing
16 Jan 2026
Next filing
09 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Howze Yalonda INTERIM CEO & PRESIDENT C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE /s/ Shawna-Gay White, Attorney-in-Fact 04 Feb 2026 0001828153

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBIO Common Stock Options Exercise +1,673 +65% 4,254 02 Feb 2026 Direct F1
transaction GBIO Common Stock Tax liability $2,792 -495 -12% $5.64 3,759 02 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBIO Restricted Stock Units Options Exercise $0 -1,673 -100% $0.000000 0 02 Feb 2026 Common Stock 1,673 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the right to receive one share of the company's common stock.
F2 The grant of 53,550 restricted stock units was made on April 5, 2023. Pursuant to the terms of that certain Agreement and Plan of Merger, by and among the Issuer, XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp., dated as of December 15, 2025 (the "Merger Agreement"), prior to the effective time of the merger as contemplated by the Merger Agreement, each restricted stock unit of the Issuer that was outstanding and unvested became vested in full on February 2, 2026.